Drugs Made In America Acquisition Signs $1.71B M&A Deal with Power Analytics Global Corp
Drugs Made In America Acquisition Corp. entered into an amendment to its merger agreement with Power Analytics Global Corp (PAGC) to establish a standalone closing valuation of $1.71 billion. This valuation applies if PAGC's acquisition of APQC Inc is not completed by November 1, 2026, down from the original $2.85 billion valuation that included the APQC assets. The merger consideration will be paid entirely in shares at the closing with no earnout provisions.
- Value
- $1.71B
- Counterparty
- Power Analytics Global Corp